Save time and get answers to complex questions with AI chat
What is dabrafenib mesylate msn patent issue?How many years does kadcyla's market exclusivity last?What are the most memorable drug brands in oral factor b inhibitors? in united statesRegulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?Is januvia still on the market?
Short answer: Yes. WO2015134998 A1 is a patent application titled “Human plasma kallikrein inhibitors.” It relates to small-molecule inhibitors of human plasma kallikrein and includes berotralstat (a known oral plasma kallikrein inhibitor) as an example. The document is part of BioCryst’s/related assignees’ patent family covering prophylaxis/treatment of hereditary angioedema and related conditions. Where to view it: - Google Patents entry: https://patents.google.com/patent/WO2015134998A1/en - You can also see the family members (US/EP/etc.) and the status from Google Patents’ “Patent family” and “Legal events” sections. What you’ll typically find in such a patent: - Disclosed inhibitors of human plasma kallikrein, including specific small-molecule scaffolds and their salts/solvates. - Examples that include berotralstat as a representative compound. - Methods of using these inhibitors to treat or prevent hereditary angioedema and related conditions. - Descriptions of pharmaceutical compositions, dosing considerations, and potential formulations. If you’d like, I can: - Pull out the exact Claim 1 language or summarize the main claims. - Highlight the key chemical scaffolds and representative examples. - Check the current legal status and relate it to berotralstat’s approved product (Orladeyo) and its patent landscape.
Other Questions About Human :